Important notice: This article is for educational and informational purposes only and does not constitute medical advice. GLP-1 medications are prescription drugs that require evaluation, prescription, and monitoring by a licensed healthcare professional. Compounded medications discussed here have not been reviewed or approved by the FDA for safety, effectiveness, or quality. All medical decisions — including whether to start, continue, or stop any medication — must be made in consultation with a licensed clinician. If you experience a severe adverse reaction, seek immediate medical attention.
GLP-1 Side Effects: What This Article Covers
Wellorithm connects eligible patients with licensed clinicians for evaluation and, when medically appropriate, access to compounded GLP-1 medications — primarily compounded semaglutide and compounded tirzepatide. Before enrolling in any GLP-1 program, understanding the side effect profile is a basic prerequisite for informed consent. This article covers what the peer-reviewed clinical literature and FDA-approved labeling document about GLP-1 receptor agonist side effects, how they are typically managed, the contraindications that make these medications inappropriate for certain patients, and the monitoring steps that responsible programs should include.
This is not a Wellorithm-specific safety file. There is no published independent clinical safety data specific to Wellorithm's compounded formulations. The safety information here is drawn from the peer-reviewed literature and FDA labeling for the GLP-1 drug class — semaglutide and tirzepatide — which is the relevant clinical basis for evaluating this category of medication. For the full review of Wellorithm's program and pricing terms, see our Wellorithm review. For a breakdown of the semaglutide mechanism, see our Wellorithm semaglutide breakdown.
Common Side Effects: Gastrointestinal
The most frequently reported side effects of GLP-1 receptor agonists are gastrointestinal, and this pattern is consistent across the STEP trial data for semaglutide and the SURMOUNT trial data for tirzepatide published in peer-reviewed literature. These effects are primarily a consequence of the mechanism itself — slowing gastric emptying and altering gut motility produces predictable GI effects in a meaningful proportion of patients.
Nausea is the most commonly reported side effect. In the STEP 1 trial data published in the New England Journal of Medicine, nausea was reported in approximately 44% of semaglutide participants compared with approximately 16% of placebo participants during the trial. It is most common in the early weeks of treatment and typically diminishes with continued use, particularly after the initial titration period stabilizes. Eating smaller meals, eating slowly, and avoiding high-fat or highly spiced foods are commonly recommended dietary strategies during early treatment.
Vomiting and diarrhea are also reported more frequently in GLP-1 treatment groups than in placebo groups in clinical trials. Like nausea, these effects are most common during the early treatment period and during dose escalation steps. They generally diminish over time as the gastrointestinal system adjusts.
Constipation is the GI side effect that patients often find most persistent. Unlike nausea and diarrhea, which tend to peak early and resolve, constipation may persist throughout the treatment period for some patients. Adequate hydration and dietary fiber are the primary management strategies; patients experiencing significant constipation should discuss management options with their prescribing clinician.
Abdominal discomfort, bloating, and reflux are also reported. These effects are related to slower gastric emptying and may be exacerbated by meal size or composition.
Dose Titration: Why It Matters for Tolerability
The standard approach to managing GLP-1 gastrointestinal side effects is gradual dose titration — starting at the lowest dose and increasing at defined intervals rather than starting at the therapeutic dose. The FDA-approved Wegovy dosing schedule, for example, begins at 0.25 mg once weekly and increases in steps every four weeks before reaching the maintenance dose of 2.4 mg. This stepwise approach reflects clinical evidence that slower titration reduces the frequency and severity of GI side effects.
In telehealth programs, the prescribing clinician determines the titration schedule based on the patient's response and tolerability. Patients experiencing severe or persistent side effects should contact their provider — dose adjustment or a slower titration schedule may be appropriate. Patients should not self-adjust dosing without clinician guidance.
Serious Risks: What the FDA Labeling Documents
Beyond the common gastrointestinal side effects, FDA-approved labeling for semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) documents several more serious potential risks that every patient should understand before starting treatment.
Thyroid C-cell tumor risk (boxed warning): Semaglutide and tirzepatide carry an FDA boxed warning based on animal study findings showing dose-dependent increases in thyroid C-cell tumors. This risk has not been confirmed in humans and the clinical relevance to human patients is uncertain; however, both medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2). Patients with relevant family history must disclose this during the intake evaluation — these conditions are absolute contraindications.
Pancreatitis: GLP-1 receptor agonists have been associated with acute pancreatitis in clinical reports. FDA labeling for semaglutide and tirzepatide advises discontinuing the medication promptly if pancreatitis is suspected and not restarting it if pancreatitis is confirmed. Patients with a history of pancreatitis should discuss this with a clinician before initiating GLP-1 therapy.
Gallbladder disease: An increased risk of gallbladder-related adverse events, including cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation), has been reported in clinical trials of GLP-1 medications. The mechanism may relate to altered bile composition and gallbladder contractility. Patients with known gallbladder disease or symptoms of abdominal pain should discuss this with their clinician.
Hypoglycemia: GLP-1 medications stimulate insulin secretion in a glucose-dependent manner, which generally makes hypoglycemia less likely than with some other diabetes medications. However, patients taking concomitant insulin or insulin secretagogues (sulfonylureas) are at increased risk for hypoglycemia when adding a GLP-1 medication. Medication interactions must be disclosed during the intake evaluation.
Heart rate increase: GLP-1 receptor agonists have been associated with a modest increase in resting heart rate. Clinical trials have not shown cardiovascular harm from this effect — in fact, some GLP-1 medications have demonstrated cardiovascular benefit in specific patient populations in long-term trials. However, patients with pre-existing tachycardia or relevant cardiovascular conditions should discuss this with their clinician.
Contraindications: Who Should Not Use GLP-1 Medications
Per FDA-approved labeling for semaglutide and tirzepatide, the following are absolute contraindications:
Personal or family history of medullary thyroid carcinoma. Personal or family history of multiple endocrine neoplasia syndrome type 2 (MEN 2). Known hypersensitivity to semaglutide or tirzepatide, respectively, or any component of the formulation.
These are hard stops. Patients with any of these conditions are not candidates for GLP-1 therapy and should not enroll in any program offering these medications. Accurate disclosure during the intake questionnaire is the mechanism through which the prescribing clinician identifies and screens for these contraindications. Incomplete disclosure creates clinical risk.
Additionally, GLP-1 medications are not approved for use in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
What Responsible Monitoring Looks Like
GLP-1 therapy is not a one-time prescription interaction. Responsible programs include follow-up monitoring to assess tolerability, track weight changes, manage side effects, and adjust dosing when appropriate. Patients evaluating any telehealth GLP-1 program — including Wellorithm — should confirm what ongoing monitoring is included in the program pricing and how to reach a provider if side effects emerge between scheduled consultations.
Wellorithm's published program description includes 24/7 support access by phone at +1 (877) 402-6778. Patients should confirm the process for reporting adverse effects and accessing clinical review if symptoms emerge.
Muscle Loss: A Consideration for Long-Term Programs
One consideration that has received increasing attention in discussions of GLP-1 weight loss programs is lean body mass loss. Clinical trial data suggest that a portion of weight lost during GLP-1 therapy may include lean muscle mass, not only fat tissue. The proportion of lean mass loss varies across individuals and studies. In clinical trial settings, this concern has been addressed through recommendations for adequate protein intake and resistance exercise during the treatment period. Patients in telehealth programs should discuss protein targets and exercise recommendations with their clinician at the outset of treatment — this is an area where behavioral guidance alongside medication management matters.
For More Information
For the complete program review including pricing and refund terms, see the Wellorithm review. For the full index of GLP-1 telehealth platform reviews on this site, see our weight management research hub.
Frequently Asked Questions
What are the most common side effects of GLP-1 medications like those offered through Wellorithm? The most common side effects reported in clinical trials of GLP-1 receptor agonists including semaglutide and tirzepatide are gastrointestinal in nature: nausea, vomiting, diarrhea, constipation, and abdominal discomfort. These effects are most common during the early weeks of treatment and during dose increases. They often diminish as the body adjusts to the medication.
Are there serious risks associated with semaglutide or tirzepatide? Rare but serious risks identified in clinical research and FDA-approved labeling include pancreatitis, gallbladder disease, and a boxed warning for a risk of thyroid C-cell tumors observed in animal studies. The thyroid tumor risk has not been confirmed in humans, but semaglutide and tirzepatide are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. All risks should be discussed with a licensed clinician before starting treatment.
How are GLP-1 side effects managed? Common gastrointestinal side effects are typically managed through gradual dose titration — starting at a low dose and increasing slowly — along with dietary adjustments such as eating smaller meals, avoiding high-fat or high-sugar foods, and staying hydrated. If side effects are severe or persistent, the prescribing clinician may adjust the dosing schedule or evaluate whether the medication is appropriate to continue.
Who should not take GLP-1 medications? Per FDA-approved labeling for semaglutide and tirzepatide, these medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. They should be used with caution in patients with a history of pancreatitis. Other contraindications and precautions exist — a complete medical evaluation by a licensed clinician is required before prescribing.